Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Tianjin Lisheng Pharmaceutical Co Ltd cash flow-to-debt ratio. Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow-to-Debt Ratio of 0.32x as of December 2025, meaning its operating cash flow of CN¥287.81 Million could theoretically repay 0% of its total liabilities (CN¥890.89 Million) in one year. Check 002393 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Cash flow-to-debt ratio of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2025. Historical debt coverage capacity for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Check 002393 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2007–2025)
Tianjin Lisheng Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Tianjin Lisheng Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Tianjin Lisheng Pharmaceutical Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥451.85 Million | CN¥890.89 Million | ▲ +466.3% |
| 2024 | 0.09x | CN¥88.26 Million | CN¥985.54 Million | ▼ -62.5% |
| 2023 | 0.24x | CN¥209.51 Million | CN¥877.17 Million | ▼ -32.1% |
| 2022 | 0.35x | CN¥331.38 Million | CN¥941.66 Million | ▲ +39.9% |
| 2021 | 0.25x | CN¥196.34 Million | CN¥780.42 Million | ▲ +137.2% |
| 2020 | 0.11x | CN¥76.37 Million | CN¥720.09 Million | ▼ -66.2% |
| 2019 | 0.31x | CN¥268.33 Million | CN¥855.85 Million | ▲ +35.8% |
| 2018 | 0.23x | CN¥162.69 Million | CN¥704.85 Million | ▼ -22.4% |
| 2017 | 0.30x | CN¥179.25 Million | CN¥602.32 Million | ▼ -19.3% |
| 2016 | 0.37x | CN¥173.60 Million | CN¥470.60 Million | ▼ -18.2% |
| 2015 | 0.45x | CN¥198.13 Million | CN¥439.50 Million | ▲ +110.9% |
| 2014 | 0.21x | CN¥72.24 Million | CN¥337.89 Million | ▼ -78.0% |
| 2013 | 0.97x | CN¥289.62 Million | CN¥298.20 Million | ▼ -42.6% |
| 2012 | 1.69x | CN¥250.72 Million | CN¥148.13 Million | ▼ -19.4% |
| 2011 | 2.10x | CN¥134.58 Million | CN¥64.07 Million | ▼ -13.2% |
| 2010 | 2.42x | CN¥186.55 Million | CN¥77.12 Million | ▲ +407.2% |
| 2009 | 0.48x | CN¥196.14 Million | CN¥411.26 Million | ▲ +1.9% |
| 2008 | 0.47x | CN¥126.59 Million | CN¥270.58 Million | ▲ +18.2% |
| 2007 | 0.40x | CN¥174.94 Million | CN¥441.87 Million | — |